Immunohistochemical analysis using antibodies that recognize active nuclear NOTCH2 in situ supports NOTCH2 activation in SMZL, but shows an expression of NICD2 in both wild-type and NOTCH2 mutant tumours [106]. This evidence concerns the gene NOTCH2 and neoplasm.